Nadia Khoury, MD
Endocrinology, Diabetes & Metabolism · Southgate, MINPI 1346446143
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $26,444 of the $32,642 with a category attached, or 81.0%. It is spread thinly across 60 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $10,850 and has fallen 61.9% since, to $4,136 in 2025.
Across 1,353 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- Novo Nordisk$4K
- Lilly USA, LLC$3K
- Corcept Therapeutics$2K
- Boehringer Ingelheim$2K
- AstraZeneca$1K
- plus $14K from 54 others
What the payments were for
- Consulting fees$1,8236%
- Speaking & faculty fees$3,25010%
- Travel & lodging$1,0163%
- Food & beverage$26,44481%
- Education$1080%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$1,823
- CeQur Simplicity$489
- Korlym$367
- TOUJEO$365
- INVOKANA$259
- SOLIQUA 100/33$250
- Repatha$235
- EVENITY$232
- CRENESSITY$136
- FARXIGA$134
- TZIELD$130
- Kerendia$125
- MOUNJARO$125
- DISEASE STATE$125
- JARDIANCE$125
- TEPEZZA$124
- Creon$120
How this compares
$32,642 in reported general payments places this provider in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 500 | $1,097,039 |
| JardianceEmpagliflozin | 329 | $476,603 |
| KorlymMifepristone | 11 | $474,965 |
| TrulicityDulaglutide | 224 | $415,803 |
| MounjaroTirzepatide | 172 | $336,782 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 61 | $238,519 |
| Tresiba Flextouch U-200Insulin Degludec | 117 | $190,965 |
| FarxigaDapagliflozin Propanediol | 143 | $187,892 |
| RybelsusSemaglutide | 74 | $177,616 |
| JanuviaSitagliptin Phosphate | 116 | $159,572 |
| Humalog Kwikpen U-100Insulin Lispro | 333 | $146,679 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 524 | $132,591 |
| Novolog FlexpenInsulin Aspart | 317 | $122,512 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 61 | $66,728 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $64,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $4,223 | $1,301,064627 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $3,180 | $769,289444 claims |
| Boehringer IngelheimJardiance, Glyxambi | $1,528 | $496,359343 claims |
| Corcept TherapeuticsKorlym | $1,740 | $474,96511 claims |
| AstraZenecaFarxiga | $1,308 | $187,892143 claims |
| MerckJanuvia | $304 | $159,572116 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,271 | $79,34992 claims |
| Johnson & JohnsonInvokana | $501 | $41,50727 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $501 | $25,1011,974 claims |
| AbbVieSynthroid | $855 | $9,593135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Southgate
- Sleman KhourySouthgate$63K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
- Ashish VermaShelby Twp$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.